Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention

Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention

Not required

Bibliographic Details
Main Author:	Marco Cattaneo
Format:	Article
Language:	English
Published:	PAGEPress Publications 2023-06-01
Series:	Bleeding, Thrombosis and Vascular Biology
Subjects:	P2Y12 antiplatelet therapy cardiovascular diseases monitoring genotype platelet function tests
Online Access:	https://btvb.org/btvb/article/view/86

Similar Items

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
by: Mohamed Farag, et al.
Published: (2022-10-01)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
by: Mengjin Hu, et al.
Published: (2022-07-01)

Personalizing antiplatelet therapies: What have we learned from recent trials?
by: Sébastien Landry, et al.
Published: (2018-02-01)

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes
by: Isabella Russo, et al.
Published: (2024-04-01)

Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
by: Oliva A, et al.
Published: (2023-11-01)

Antiplatelet agents: an overview
by: Asma Haffouz, et al.
Published: (2023-01-01)

Antiplatelet drugs and liver fibrosis
by: Pamela Czajka, et al.
Published: (2022-02-01)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
by: Marie Muthspiel, et al.
Published: (2022-11-01)

Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy
by: GianMarco Podda, et al.
Published: (2018-10-01)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?
by: Zeki Öngen
Published: (2018-01-01)

De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature
by: Daniel MF Claassens, et al.
Published: (2020-09-01)

Sex differences in antiplatelet therapy: state-of-the art
by: Aleksandra Gasecka, et al.
Published: (2023-12-01)

P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
by: Yanqiao Yu, et al.
Published: (2023-07-01)

Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions
by: Mattia Galli, et al.
Published: (2023-03-01)

Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients
by: Valentine Robaux, et al.
Published: (2023-12-01)

Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
by: Anne Godier, et al.
Published: (2020-07-01)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
by: Zhigang Zhao, et al.
Published: (2023-03-01)

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
by: Si-Qi Lyu, et al.
Published: (2020-11-01)

Income and antiplatelet adherence following percutaneous coronary intervention
by: Anna R. LaRosa, et al.
Published: (2022-09-01)

Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1‐Year Results of the PENDULUM Registry
by: Masato Nakamura, et al.
Published: (2020-05-01)

P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
by: Sohyun Park, et al.
Published: (2021-03-01)

Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
by: Dimitrios Alexopoulos, et al.
Published: (2018-04-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

Efficiency and safety of various dual antiplatelet therapy strategies in patients undergoing percutaneous coronary intervention due to myocardial infarction
by: S. B. Aksentiev, et al.
Published: (2021-08-01)

Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells
by: Omar Elaskalani, et al.
Published: (2020-01-01)

P2Y<sub>12</sub> Inhibitor Monotherapy after Percutaneous Coronary Intervention
by: Xuan Zhou, et al.
Published: (2022-10-01)

Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y<sub>12</sub> Inhibitors and Their Association with Platelet Function
by: Karolina Gumiężna, et al.
Published: (2023-12-01)

Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention
by: Pei Zhu, et al.
Published: (2019-10-01)

Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
by: Abdullah Al-abcha, et al.
Published: (2022-03-01)

Guided vs. conventional anti-platelet therapy for patients with acute coronary syndrome: A meta-analysis of randomized controlled trials
by: Peng-Yu Zhong, et al.
Published: (2023-03-01)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
by: Wen-Han Feng, et al.
Published: (2022-04-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention
by: Gelena Berezovskaya, et al.
Published: (2018-02-01)

Total Thrombus‐formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
by: Yu Oimatsu, et al.
Published: (2017-04-01)

Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
by: Felice Gragnano, et al.
Published: (2023-12-01)

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring
by: Grzegorz Procyk, et al.
Published: (2022-03-01)

Identification of Potential Drug Targets for Antiplatelet Therapy Specifically Targeting Platelets of Old Individuals through Proteomic Analysis
by: Seung Hee Lee, et al.
Published: (2023-10-01)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
by: Yu-Wei Chen, et al.
Published: (2022-08-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Novel antiplatelet targets in the treatment of acute coronary syndromes
by: Fawaz O. Alenazy, et al.
Published: (2021-01-01)